Colitis Treatments
Find Colitis Treatments
Medications for Colitis
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Colitis.
Found 28 Approved Drugs for Colitis
Infliximab
Brand Names
Avsola, Inflectra, Remicade, Renflexis, Zymfentra
Infliximab
Brand Names
Avsola, Inflectra, Remicade, Renflexis, Zymfentra
Form: Injection, Kit
Method of administration: Subcutaneous, Intravenous
FDA approval date: August 24, 1998
Classification: Tumor Necrosis Factor Blocker
AVSOLA is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease : reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy.
Mesalamine
Brand Names
Apriso, Canasa, Lialda, Pentasa, Rowasa
Mesalamine
Brand Names
Apriso, Canasa, Lialda, Pentasa, Rowasa
Form: Suppository, Tablet, Enema, Kit, Suspension, Capsule
Method of administration: Oral, Rectal
FDA approval date: May 10, 1993
Classification: Aminosalicylate
APRISO is indicated for the maintenance of remission of ulcerative colitis in adults. APRISO is an aminosalicylate indicated for the maintenance of remission of ulcerative colitis in adults. ( 1 )
Entyvio
Generic Name
Vedolizumab
Entyvio
Generic Name
Vedolizumab
Form: Injection
Method of administration: Subcutaneous, Intravenous
FDA approval date: May 20, 2014
Classification: Integrin Receptor Antagonist
ENTYVIO is indicated in adults for the treatment of: moderately to severely active ulcerative colitis. moderately to severely active Crohn's disease. ENTYVIO is an integrin receptor antagonist indicated in adults for the treatment of: moderately to severely active ulcerative colitis. ( 1 ) moderately to severely active Crohn's disease. ( 1 )
Sulfasalazine
Brand Names
Azulfidine, Azulfidine EN-tabs
Sulfasalazine
Brand Names
Azulfidine, Azulfidine EN-tabs
Form: Tablet
Method of administration: Oral
FDA approval date: June 20, 1950
Classification: Aminosalicylate
AZULFIDINE Tablets are indicated: in the treatment of mild to moderate ulcerative colitis, and as adjunctive therapy in severe ulcerative colitis; and, for the prolongation of the remission period between acute attacks of ulcerative colitis.
Ustekinumab
Brand Names
Otulfi, Pyzchiva, Selarsdi, Starjemza, Stelara, Steqeyma, Ustekinumab-AAUZ, Ustekinumab-aekn, Ustekinumab-TTWE, Wezlana, Yesintek
Ustekinumab
Brand Names
Otulfi, Pyzchiva, Selarsdi, Starjemza, Stelara, Steqeyma, Ustekinumab-AAUZ, Ustekinumab-aekn, Ustekinumab-TTWE, Wezlana, Yesintek
Form: Injection, Solution
Method of administration: Subcutaneous, Intravenous
FDA approval date: September 25, 2009
Classification: Interleukin-12 Antagonist
OTULFI is a human interleukin-12 and -23 antagonist indicated for the treatment of: Adult patients with: moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy.
Showing 1-5 of 28
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances